NOXXON Pharma KOL Webinar on NOX-A12 & Radiotherapy Combination: A Differentiated and Promising New Approach to Treating Brain Cancer
About The Event
The webinar will feature a presentation from Frank A. Giordano, M.D. (Chair of the Dept. of Radiation Oncology, University Hospital Bonn – Germany), who will discuss the current treatment landscape and high unmet medical need in treating patients with brain cancer (glioblastoma multiforme, GBM).
Following his presentation at the Society for Neuro-Oncology (SNO) Annual Meetingon November 19, Dr. Giordano will further discuss the latest promising patient results from the GLORIA study, evaluating NOX-A12 in combination with radiotherapy in first-line brain cancer patients with unmethylated MGMT promoter.
NOX-A12 is an inhibitor of the chemokine CXCL12 and has been granted orphan drug status in the US and EU for the treatment of certain brain cancers and produced encouraging clinical data thus far. Dr. Giordano will also compare NOXXON’s trial data to historical data evaluating how a matched patient cohort responded to the treatment according to current standard of care, which has remained unchanged since 2006.
NOXXON’s management team will also give a corporate overview and an update on clinical programs. Dr. Giordano will be available for questions following the formal presentation.